Results 131 to 140 of about 11,335 (243)

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang   +3 more
wiley   +1 more source

PTGES3 proteolysis using the liposomal peptide-PROTAC approach

Biology Direct
Background Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide, and the lack of effective biomarkers for early detection leads to poor therapeutic outcomes.
Shiwei Liu, Fukang Yuan, Hui Dong, Jiaqi Zhang, Xinyu Mao, Yangsui Liu, Huansong Li   +6 more
doaj   +1 more source

Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Cellular senescence shapes tumor progression through both antitumor and protumor mechanisms. Senescence triggered by telomere shortening restricts malignant transformation and limits tumor cell proliferation, while the senescence‐associated secretory phenotype (SASP) secretion enhances antitumor immunity by activating cytotoxic T cells.
Huajie Mao, Wanning Liu, Yuanyuan Su, Yuxuan Ma, Xiaodi Zhao, Yuanyuan Lu   +5 more
wiley   +1 more source

Covalent Peptide‐Based N‐Myc/Aurora‐A Inhibitors Bearing Sulfonyl Fluoride Warheads

Journal of Peptide Science, Volume 32, Issue 3, March 2026.
N‐Myc‐derived peptidomimetics bearing aryl sulfonyl fluoride warheads were shown to act as effective N‐Myc/Aurora‐A PPI inhibitors, selectively labelling Aurora‐A in a recognition‐directed manner. ABSTRACT Orthosteric inhibition of the N‐Myc/Aurora‐A protein–protein interaction (PPI) represents a potential mechanism by which degradation of N‐Myc can be
Robert S. Dawber, Diana Gimenez, George W. Preston, Megan H. Wright, Richard Bayliss, Stuart L. Warriner, Andrew J. Wilson   +6 more
wiley   +1 more source

KCTD15 Enhances Stem Cell‐Like Properties and Promotes Triple‐Negative Breast Cancer Progression Through KLF4/β‐Catenin Signaling

The FASEB Journal, Volume 40, Issue 4, 28 February 2026.
KCTD15 is upregulated in TNBC tissues and cells. It enhances TNBC stemness via KLF4/β‐catenin signaling, promotes proliferation, migration, and stemness while inhibiting apoptosis, and drives tumorigenesis in vivo. Collectively, Feng et al.' study reveals that KCTD15 acts as a key oncogenic driver in TNBC via the KLF4/β‐catenin axis, highlighting its ...
Liang Yao, Wei Sun, Jun Xing, Jing Feng
wiley   +1 more source

A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
A robust C(sp2)–C(sp3) decarboxylative coupling strategy enables access to new CRBN ligands and degraders with improved physicochemical properties. This synthetic approach is expanding the chemical space beyond C(sp2)–N linkages, fine‐tuning proteolysis‐targeting chimera activities and unlocking previously inaccessible degrader chemotypes.
Anita Maksutova, Thomas M. Geiger, Lorenzo Cianni, Dominika E. Pieńkowska, Jan Gerhartz, Lina Read, Aleša Bricelj, Alexander Herrmann, Maurice Leon Nelles, Yuen Lam Dora Ng, Marcus D. Hartmann, Jan Krönke, Izidor Sosič, Radosław P. Nowak, Michael Gütschow, Christian Steinebach   +15 more
wiley   +1 more source

Editorial: The challenge of immunity evaluation and immunotherapy in gynecologic and urologic oncology

Frontiers in Immunology, 2023
Ruirong Tan, Miao Liu, Yiguan Zhang, Rui Li   +3 more
doaj   +1 more source

Direct‐to‐Biology: Streamlining the Path From Chemistry to Biology in Drug Discovery

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
Crude yet clever: Direct‐to‐biology workflows exploit nanoscale synthesis and plate‐based assays to accelerate hit discovery, save precious intermediates, and rethink early drug discovery. Direct‐to‐biology (D2B) has emerged as a transformative concept in early drug discovery, defined by the direct on‐target screening of crude reaction mixtures without
Ariane F. Hübner, Fabian Barthels
wiley   +1 more source

Peripheral RIPK2 degradation improves neurological outcomes after experimental ischemic stroke. [PDF]

J Cereb Blood Flow Metab
Howell JA, Larochelle J, Strawser M, De La Vega Mulet S, Tishko R, Gunraj R, Liu L, Candelario-Jalil E.   +7 more
europepmc   +1 more source

Revolutionizing protein degradation: Harnessing nanoparticles for PROTAC delivery. [PDF]

Mater Today Bio
Fan Y, Su J, Yang J, Guan X, Gong Y, Yang D, Qin A, Zhang L.   +7 more
europepmc   +1 more source